Cargando…

Longitudinal Analysis of T and B Cell Phenotype and Function in Renal Transplant Recipients with or without Rituximab Induction Therapy

BACKGROUND: Prevention of rejection after renal transplantation requires treatment with immunosuppressive drugs. Data on their in vivo effects on T- and B-cell phenotype and function are limited. METHODS: In a randomized double-blind placebo-controlled study to prevent renal allograft rejection, pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamburova, Elena G., Koenen, Hans J. P. M., van den Hoogen, Martijn W. F., Baas, Marije C., Joosten, Irma, Hilbrands, Luuk B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231065/ https://www.ncbi.nlm.nih.gov/pubmed/25393622 http://dx.doi.org/10.1371/journal.pone.0112658

Ejemplares similares

Absence of Intragraft B Cells in Rejection Biopsies After Rituximab Induction Therapy: Consequences for Clinical Outcome
por: van den Hoogen, Martijn W.F., et al.
Publicado: (2017)

Immunological Monitoring of Renal Transplant Recipients to Predict Acute Allograft Rejection Following the Discontinuation of Tacrolimus
por: Kreijveld, Ellen, et al.
Publicado: (2008)

Ex Vivo Generation of Human Alloantigen-Specific Regulatory T Cells from CD4(pos)CD25(high) T Cells for Immunotherapy
por: Peters, Jorieke H., et al.
Publicado: (2008)

Clinical Grade Treg: GMP Isolation, Improvement of Purity by CD127(pos) Depletion, Treg Expansion, and Treg Cryopreservation
por: Peters, Jorieke H., et al.
Publicado: (2008)

Costimulation Blockade in Kidney Transplant Recipients
por: van der Zwan, Marieke, et al.
Publicado: (2019)

A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients
por: Bunthof, Kim L. W., et al.
Publicado: (2021)

Can We Predict Graft Intolerance Syndrome After Kidney Transplant Failure? External Validation of a Previously Developed Model
por: Bunthof, Kim, et al.
Publicado: (2023)

Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group
por: Song, Young Hae, et al.
Publicado: (2012)

Nocardiosis in a renal transplant recipient following rituximab preconditioning
por: Flohr, Tanya R, et al.
Publicado: (2009)

Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders
por: Karbasi-Afshar, R, et al.
Publicado: (2013)

Predictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant Recipients
por: Frölke, Sophie C., et al.
Publicado: (2022)

Development and Validation of a Multiplex Non-HLA Antibody Assay for the Screening of Kidney Transplant Recipients
por: Kamburova, Elena G., et al.
Publicado: (2018)

Treatment of Recurrent Focal Segmental Glomerulosclerosis in Pediatric Kidney Transplant Recipients: Effect of Rituximab
por: Sethna, Christine, et al.
Publicado: (2011)

The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4(+) T cells
por: Besançon, Alix, et al.
Publicado: (2017)

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients
por: van der Zwan, Marieke, et al.
Publicado: (2020)

Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients
por: Park, Hoon Suk, et al.
Publicado: (2014)

Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab
por: Kim, Young Hoon, et al.
Publicado: (2020)

Comparative Long-Term Renal Allograft Outcomes of Recurrent Immunoglobulin A with Severe Activity in Kidney Transplant Recipients with and without Rituximab: An Observational Cohort Study
por: Chancharoenthana, Wiwat, et al.
Publicado: (2021)

Comparing the effect of induction therapy with or without antithymocyte globulin on renal allograft outcomes in live-donor kidney transplant recipients
por: Marghoob, Bahareh, et al.
Publicado: (2019)

Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients
por: Tomita, Yusuke, et al.
Publicado: (2019)

Additional Benefits of Rituximab and Plasma Exchange on Top of Standard Induction Therapy in Kidney Transplant Recipients With a Negative CDC Crossmatch but High Preformed Donor Specific Antibody Titer
por: Mohamadou, Inna, et al.
Publicado: (2023)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Induction immunosuppression and outcome in kidney transplant recipients with early COVID-19 after transplantation
por: Toapanta, Néstor, et al.
Publicado: (2022)

Induction Therapy and Outcomes following Kidney Transplantation in Recipients of Previous Heart or Liver Transplants
por: Sureshkumar, Kalathil K., et al.
Publicado: (2022)

The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
por: An, Gun Hee, et al.
Publicado: (2014)

Rituximab Desensitization in Liver Transplant Recipients With Preformed Donor-specific HLA Antibodies: A Japanese Nationwide Survey
por: Akamatsu, Nobuhisa, et al.
Publicado: (2021)

Rituximab in kidney disease and transplant
por: Chauhan, Kajal, et al.
Publicado: (2019)

The Risk of Postkidney Transplant Outcomes by Induction Choice Differs by Recipient Age
por: Ahn, JiYoon B., et al.
Publicado: (2021)

A closer look at rituximab induction on HLA antibody rebound following HLA incompatible kidney transplantation
por: Jackson, Annette M., et al.
Publicado: (2014)

CKD is a key risk factor for COVID-19 mortality
por: Gansevoort, Ron T., et al.
Publicado: (2020)

Kidney transplantation or dialysis in older adults—an interview study on the decision-making process
por: Schoot, Tessa S, et al.
Publicado: (2022)

Plasma Proenkephalin and Poor Long-Term Outcome in Renal Transplant Recipients
por: Kieneker, Lyanne M., et al.
Publicado: (2017)

Successful treatment of severe anti-p200 pemphigoid in a heart transplant recipient with a single cycle of rituximab
por: Rousseau, Lisa, et al.
Publicado: (2017)

Successful pregnancy after in vitro fertilization in an ABO-incompatible kidney transplant recipient receiving rituximab: a case report
por: Kosoku, Akihiro, et al.
Publicado: (2019)

Use of rituximab in SARS-CoV-2-positive renal transplant recipient with EBV reactivation and probable haemophagocytic lymphohistiocytosis
por: Chan, Derek, et al.
Publicado: (2022)

Maternal, Decidual, and Neonatal Lymphocyte Composition Is Affected in Pregnant Kidney Transplant Recipients
por: Feyaerts, Dorien, et al.
Publicado: (2021)

Integration of multi-omics data and deep phenotyping enables prediction of cytokine responses
por: Bakker, Olivier B., et al.
Publicado: (2018)

A Review of Induction with Rabbit Antithymocyte Globulin in Pediatric Heart Transplant Recipients
por: Schweiger, Martin, et al.
Publicado: (2018)

Rabbit Antithymocyte Globulin Induction in Heart Transplant Recipients at High Risk for Rejection
por: Kitto, Brent, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ibfrgu3bv2vsjg5f5umn1mrkgr